Drug Trial Radar · NCT01147809
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
Last checked: Nov 20, 2026Latest source record: Apr 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Jun 2010
Primary completion
Jan 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I of the study will examine safety and tolerability of various doses of eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful benefit(s) to thrombocytopenic patients by improving platelet numbers.
Conditions
- Thrombocytopaenia
Interventions
Eltrombopag olamineDrug
thrombopoietin receptor agonist
PlaceboOther
Placebo tablets with no active pharmaceutical ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase ITime frame: From Cycle 1, Day 1 (C1D1) until at least 30 days post-investigational product discontinuation (longer for AEs considered related to study participation)
- Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase ITime frame: After Baseline (C1D1), on-treatment and 30 day follow-up
- Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase ITime frame: After Baseline (C1D1), on-treatment and 30 day follow-up
- Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase ITime frame: After Baseline (C1D1), on-treatment and 30 day follow-up
- Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase ITime frame: Screening, C1D1, C2D1, C2D8, C2D15, C3D1, C4D1, C4D22, C5D1, C5D8, C6D1, C6D15
- Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase ITime frame: C2D4, C2D8, C5D8, C6D15
- Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase IITime frame: Day 1 (averaged across cycles 1 to 6)
Locations
86 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Sedona, Arizona
GSK Investigational Site
Hot Springs, Arkansas
GSK Investigational Site
Rancho Cucamonga, California
GSK Investigational Site
Norwich, Connecticut
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
New Port Richey, Florida
GSK Investigational Site
Rome, Georgia
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Bethesda, Maryland
GSK Investigational Site
Rockville, Maryland
GSK Investigational Site
Columbia, Missouri
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Cherry Hill, New Jersey
GSK Investigational Site
Albany, New York
GSK Investigational Site
Greensboro, North Carolina
GSK Investigational Site
Bend, Oregon
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Wynnewood, Pennsylvania
GSK Investigational Site
Providence, Rhode Island
GSK Investigational Site
Providence, Rhode Island
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Arlington, Texas
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Bedford, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Tyler, Texas
GSK Investigational Site
Norfolk, Virginia
GSK Investigational Site
Edmonds, Washington
GSK Investigational Site
Tacoma, Washington
GSK Investigational Site
Vancouver, Washington
GSK Investigational Site
Yakima, Washington
GSK Investigational Site
Charleroi, Belgium
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Libramont, Belgium
GSK Investigational Site
Namur, Belgium
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Olomouc, Czechia
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.